KR102671166B1 - 3,5-디페닐-디아졸 화합물의 수용성 유도체 - Google Patents
3,5-디페닐-디아졸 화합물의 수용성 유도체 Download PDFInfo
- Publication number
- KR102671166B1 KR102671166B1 KR1020187020192A KR20187020192A KR102671166B1 KR 102671166 B1 KR102671166 B1 KR 102671166B1 KR 1020187020192 A KR1020187020192 A KR 1020187020192A KR 20187020192 A KR20187020192 A KR 20187020192A KR 102671166 B1 KR102671166 B1 KR 102671166B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- disease
- amyloidosis
- compounds
- delete delete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199972 | 2015-12-14 | ||
| EP15199972.9 | 2015-12-14 | ||
| PCT/EP2016/081084 WO2017102893A1 (en) | 2015-12-14 | 2016-12-14 | Water-soluble derivatives of 3,5-diphenyl-diazole compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180089511A KR20180089511A (ko) | 2018-08-08 |
| KR102671166B1 true KR102671166B1 (ko) | 2024-05-31 |
Family
ID=54850017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187020192A Active KR102671166B1 (ko) | 2015-12-14 | 2016-12-14 | 3,5-디페닐-디아졸 화합물의 수용성 유도체 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10308671B2 (enExample) |
| EP (1) | EP3390412B1 (enExample) |
| JP (1) | JP6898931B2 (enExample) |
| KR (1) | KR102671166B1 (enExample) |
| CN (1) | CN108473516B (enExample) |
| AU (1) | AU2016372408B2 (enExample) |
| BR (1) | BR112018011994B1 (enExample) |
| CA (1) | CA3008334C (enExample) |
| CL (1) | CL2018001570A1 (enExample) |
| DK (1) | DK3390412T3 (enExample) |
| ES (1) | ES2873510T3 (enExample) |
| HU (1) | HUE054815T2 (enExample) |
| IL (1) | IL260011B (enExample) |
| MX (1) | MX379522B (enExample) |
| NZ (1) | NZ742979A (enExample) |
| PH (1) | PH12018501276A1 (enExample) |
| PL (1) | PL3390412T3 (enExample) |
| PT (1) | PT3390412T (enExample) |
| RU (1) | RU2764131C2 (enExample) |
| WO (1) | WO2017102893A1 (enExample) |
| ZA (1) | ZA201803865B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH713150A2 (fr) * | 2016-11-23 | 2018-05-31 | Eta Sa Mft Horlogere Suisse | Mécanisme régulateur à résonateur rotatif à guidage flexible entretenu par un échappement libre à ancre. |
| US10368502B2 (en) | 2017-09-25 | 2019-08-06 | Multiple Energy Technologies Llc | Bioceramic and carbon-based hydroponic systems, methods and devices |
| EP4368184A3 (en) | 2019-11-19 | 2024-07-31 | Modag GmbH | Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein |
| US20250161273A1 (en) * | 2022-03-01 | 2025-05-22 | Modag Gmbh | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
| CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
| CN116399983B (zh) * | 2023-06-09 | 2023-08-15 | 天津辰欣药物研究有限公司 | 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011522810A (ja) | 2008-06-09 | 2011-08-04 | ルートヴィヒ‐マクシミリアンズ‐ウニヴェルジテート・ミュンヘン | タンパク質凝集関連の疾患および／または神経変性性疾患に関係するタンパク質の凝集を阻害するための新規薬物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| NZ564326A (en) * | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| EP2272822A4 (en) * | 2008-03-31 | 2012-01-18 | Renascience Co Ltd | PLASMINOG ACTIVATOR-1 HEMMER |
| JP6069661B2 (ja) * | 2010-06-24 | 2017-02-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用 |
| SMT201700306T1 (it) * | 2012-06-08 | 2017-07-18 | Theravance Biopharma R&D Ip Llc | Inibitori di neprilisina |
-
2016
- 2016-12-14 KR KR1020187020192A patent/KR102671166B1/ko active Active
- 2016-12-14 EP EP16809425.8A patent/EP3390412B1/en active Active
- 2016-12-14 CA CA3008334A patent/CA3008334C/en active Active
- 2016-12-14 BR BR112018011994-6A patent/BR112018011994B1/pt active IP Right Grant
- 2016-12-14 ES ES16809425T patent/ES2873510T3/es active Active
- 2016-12-14 HU HUE16809425A patent/HUE054815T2/hu unknown
- 2016-12-14 WO PCT/EP2016/081084 patent/WO2017102893A1/en not_active Ceased
- 2016-12-14 RU RU2018125590A patent/RU2764131C2/ru active
- 2016-12-14 MX MX2018006877A patent/MX379522B/es unknown
- 2016-12-14 CN CN201680073089.1A patent/CN108473516B/zh active Active
- 2016-12-14 DK DK16809425.8T patent/DK3390412T3/da active
- 2016-12-14 US US16/062,258 patent/US10308671B2/en active Active
- 2016-12-14 JP JP2018532323A patent/JP6898931B2/ja active Active
- 2016-12-14 PL PL16809425T patent/PL3390412T3/pl unknown
- 2016-12-14 AU AU2016372408A patent/AU2016372408B2/en active Active
- 2016-12-14 NZ NZ742979A patent/NZ742979A/en unknown
- 2016-12-14 PT PT168094258T patent/PT3390412T/pt unknown
-
2018
- 2018-06-11 ZA ZA2018/03865A patent/ZA201803865B/en unknown
- 2018-06-13 IL IL260011A patent/IL260011B/en unknown
- 2018-06-13 CL CL2018001570A patent/CL2018001570A1/es unknown
- 2018-06-14 PH PH12018501276A patent/PH12018501276A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011522810A (ja) | 2008-06-09 | 2011-08-04 | ルートヴィヒ‐マクシミリアンズ‐ウニヴェルジテート・ミュンヘン | タンパク質凝集関連の疾患および／または神経変性性疾患に関係するタンパク質の凝集を阻害するための新規薬物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108473516B (zh) | 2021-06-18 |
| RU2018125590A (ru) | 2020-01-20 |
| CA3008334C (en) | 2024-01-02 |
| ZA201803865B (en) | 2019-04-24 |
| DK3390412T3 (da) | 2021-06-21 |
| RU2764131C2 (ru) | 2022-01-13 |
| KR20180089511A (ko) | 2018-08-08 |
| PL3390412T3 (pl) | 2021-10-25 |
| CA3008334A1 (en) | 2017-06-22 |
| PH12018501276A1 (en) | 2019-01-28 |
| ES2873510T3 (es) | 2021-11-03 |
| IL260011B (en) | 2021-12-01 |
| PT3390412T (pt) | 2021-06-22 |
| US20180370997A1 (en) | 2018-12-27 |
| MX2018006877A (es) | 2018-09-18 |
| IL260011A (en) | 2018-07-31 |
| CL2018001570A1 (es) | 2018-12-28 |
| JP2019501167A (ja) | 2019-01-17 |
| EP3390412B1 (en) | 2021-04-14 |
| MX379522B (es) | 2025-03-10 |
| WO2017102893A1 (en) | 2017-06-22 |
| CN108473516A (zh) | 2018-08-31 |
| RU2018125590A3 (enExample) | 2020-04-21 |
| AU2016372408A1 (en) | 2018-06-21 |
| NZ742979A (en) | 2022-05-27 |
| US10308671B2 (en) | 2019-06-04 |
| JP6898931B2 (ja) | 2021-07-07 |
| BR112018011994A2 (pt) | 2018-12-04 |
| BR112018011994B1 (pt) | 2022-07-19 |
| EP3390412A1 (en) | 2018-10-24 |
| HUE054815T2 (hu) | 2021-10-28 |
| AU2016372408B2 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102671166B1 (ko) | 3,5-디페닐-디아졸 화합물의 수용성 유도체 | |
| CN102256959B (zh) | 用于治疗的噻吩化合物 | |
| EA025033B1 (ru) | Диаминиевые соли фенотиазина и их применение | |
| WO2018096504A1 (en) | Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs | |
| JP2007516940A (ja) | 改善された薬剤候補およびその調製法 | |
| JP2012176963A (ja) | 改善された薬剤候補およびその調製法 | |
| US10723716B2 (en) | Alpha-helix mimetics as modulators of Abeta self-assembly | |
| JP6445046B2 (ja) | １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ | |
| US20210205348A1 (en) | Methods for the Treatment of Bladder Cancer | |
| CN120040470A (zh) | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 | |
| TW202340195A (zh) | 作為嗜中性白血球彈性蛋白酶抑制劑之三唑酮衍生物鹽 | |
| JP7828354B2 (ja) | 中枢神経系への低疎水性の生物活性薬に対して化学的にカップリングされたトランスポーター | |
| US20250002436A1 (en) | Naphthoquinone-based chalcone derivatives and uses thereof | |
| US11124479B2 (en) | Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization | |
| WO2024206127A2 (en) | Compounds, compositions, and method of inhibiting tau protein and alpha-synuclein aggregation | |
| EP3368505A1 (en) | Quinoline amides and methods of using same | |
| Dewangan et al. | Identification of A Fluorinated Triazole Amide as Multifunctional Neuroprotective Amyloid Β Aggregation Inhibitor Which Restores Mitochondria Membrane Potential (Mmp) and Downregulates Nlrp3-Il-1ß Signalling Cascade | |
| WO2018217138A1 (ru) | Новый мультитаргетный препарат для лечения заболеваний у млекопитающих |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20180713 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211015 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20231204 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20240306 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240528 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240529 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |